Improving clinical outcomes of patients with hepatocellular carcinoma: Role of antiviral therapy, conversion therapy, and palliative therapy

doi:10.4251/wjgo.v16.i10.4037

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (957)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

682

Sum=705

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

104

Sum=178

Publishing Process of This Article

Item

Count

Browse

Download

Sum=48

Oct 15, 2024 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastrointest Oncol. Oct 15, 2024; 16(10): 4037-4041
Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4037

Improving clinical outcomes of patients with hepatocellular carcinoma: Role of antiviral therapy, conversion therapy, and palliative therapy

Vishal G Shelat

Vishal G Shelat, Department of General Surgery, Tan Tock Seng Hospital, Singapore 308433, Singapore

Author contributions: Shelat VG contributed to the conception and design of the study, acquisition of data, analysis and interpretation of data, drafting the article, revising the article, critical revision, and final approval.

Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Vishal G Shelat, DNB, FICS, FRCS (Ed), MBBS, MMed, MNAMS, MS, Adjunct Associate Professor, Department of General Surgery, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore. vgshelat@rediffmail.com

Received: February 24, 2024
Revised: May 17, 2024
Accepted: June 14, 2024
Published online: October 15, 2024
Processing time: 215 Days and 1.8 Hours

Core Tip

Core Tip: Hepatocellular carcinoma (HCC) is a common cancer, and the treatment approaches are evolving. The outcomes of liver resection patients can be improved by early diagnosis, robust implementation of screening programs, and pre-operative antiviral therapy for patients who qualify for it. In patients managed with multimodality treatment, downstaging and conversion to surgical resection remain possible. Simple serological markers can be useful for predicting the response to curative or palliative intent treatment of HCC patients.